Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook
Maravai LifeSciences Holdings (NasdaqGS:MRVI) reported a significant Q1 2026 turnaround with a 41% revenue jump, narrowed net loss, and positive Adjusted EBITDA, driven by a large CleanCap vaccine order and debt reduction. The strong performance has led to a re-evaluation of the company's risk profile, with the stock price increasing substantially over the past year. Investors are now focused on whether this trend is sustainable or a one-off event.
12 West Capital Amends 13G, Holds 7.26M Shares in Maravai (MRVI)
12 West Capital Management and Joel Ramin have filed an amended 13G, reporting beneficial ownership of 7,260,195 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI), which represents a 4.9% stake in the company. This percentage is calculated based on 146,383,162 shares outstanding as of February 19, 2026. The filing indicates shared voting and dispositive power over these shares, and it is considered a neutral filing as the stake is below the 5% reporting threshold for different obligations.
Stuart Feldman-led group reports 9.21% stake in Maravai (MRVI)
A group led by Stuart Feldman has filed an amended Schedule 13G/A, disclosing a passive beneficial ownership of 13,488,799 shares of Maravai LifeSciences Holdings, Inc. Class A common stock, representing 9.21% of the class. Stuart Feldman individually holds 10,337,680 shares (7.06%). The filing details the sole voting and dispositive power for each member of the group, which also includes entities like Hudson View Holdings LLC and individuals like Matthew Barkoff and Joshua Wool.
Millennium group lists 4.9% holding in Maravai (NASDAQ: MRVI) on 13G
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G reporting a shared voting and dispositive power over 7,228,864 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock, which represents a 4.9% stake. The filing indicates they had briefly exceeded 5% beneficial ownership on May 6, 2026, but were below that threshold by the filing date, with a Joint Filing Agreement dated May 11, 2026. This is a passive investment disclosure, as indicated by the use of Schedule 13G.
Maravai LifeSciences (NASDAQ: MRVI) boosts Q1 revenue, cuts debt
Maravai LifeSciences reported significantly improved financial results for Q1 2026, with revenue increasing by 40.5% to $65.8 million, driven largely by its TriLink segment and $14.3 million in CleanCap® COVID-19 vaccine orders. The net loss narrowed to $6.4 million, and Adjusted EBITDA turned profitable at $20.3 million, aided by a 2025 Corporate Realignment Plan that reduced operating expenses. The company also voluntarily prepaid $50.0 million of its Term Loan, reducing long-term debt to $242.9 million by quarter-end.
Maravai LifeSciences Reports First Quarter 2026 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported strong first-quarter 2026 financial results, with total revenue up 41% year-over-year to $65.8 million, driven by demand in its TriLink base business and high-volume CleanCap orders. The company achieved positive free cash flow of $4.2 million and significantly increased its full-year 2026 revenue and Adjusted EBITDA guidance. These results reflect improved operational efficiency and a confident outlook for sustained profitable growth.
Maravai LifeSciences Reports First Quarter 2026 Financial Results
Maravai LifeSciences announced strong first-quarter 2026 financial results, with total revenue up 41% to $65.8 million and Adjusted EBITDA reaching $20.3 million. The company returned to positive free cash flow, generating $4.2 million, and raised its full-year 2026 revenue and Adjusted EBITDA guidance due to improving demand in its core TriLink business and operational efficiencies. TriLink's base non-COVID revenue grew 15% year-over-year, contributing significantly to the overall growth.
Maravai (NASDAQ: MRVI) lifts 2026 outlook after 41% Q1 revenue surge
Maravai LifeSciences (NASDAQ: MRVI) reported a strong first quarter in 2026, with revenue surging 40.5% to $65.8 million, driven by its TriLink segment and CleanCap orders. The company significantly improved profitability, narrowing its net loss and achieving positive Adjusted EBITDA and free cash flow. Consequently, Maravai raised its full-year 2026 guidance for both revenue and Adjusted EBITDA, citing improved demand and operational efficiency.
COVID vaccine orders help Maravai raise 2026 revenue targets
Maravai LifeSciences reported a 41% increase in Q1 2026 revenue to $65.8 million, driven largely by $14.3 million in high-volume CleanCap orders for commercial COVID vaccine programs. This strong performance led the company to raise its full-year 2026 revenue guidance to $205.0 million - $215.0 million and Adjusted EBITDA guidance to $30.0 million - $32.0 million. The CEO highlighted improving demand in the core TriLink base business and disciplined cost management contributing to meaningful EBITDA expansion and positive free cash flow.
Levi & Korsinsky Reminds Maravai LifeSciences Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI
Levi & Korsinsky reminds investors of a pending class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). The lawsuit alleges that Maravai made false statements and concealed issues related to revenue recognition and overstated goodwill between August 7, 2024, and February 24, 2025. Investors who suffered losses during this period are encouraged to learn about their rights to potentially recover losses, with a lead plaintiff deadline of May 5, 2025.
[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity
Christine Dolan, an officer at MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), reported a routine tax-withholding transaction. On March 16, 2026, 28,661 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations related to the vesting of restricted stock units. Following this disposition, Dolan directly holds 420,312 shares of Class A common stock.
Maravai (MRVI) General Counsel has 39,976 shares withheld for taxes
Maravai Lifesciences Holdings General Counsel Kurt Oreshack had 39,976 shares of Class A common stock withheld at $3.08 per share to cover tax obligations related to the vesting of restricted stock units. This transaction was a routine tax-withholding and not an open-market sale. Following this non-market disposition, Oreshack directly holds 384,991 shares of Maravai stock.
After $231M loss, Maravai targets $200M+ in 2026 revenue
Maravai LifeSciences reported a net loss of $230.8 million for the full year 2025, with Q4 revenue reaching $49.9 million. Despite the losses, the company provided 2026 revenue guidance of $200 million to $210 million and Adjusted EBITDA guidance of $18 million to $20 million, signaling a focus on operational excellence and revenue growth. The firm also announced organizational restructuring and operating cost reductions.
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI) and Sarepta Therapeutics (SRPT)
This article provides analyst insights on three healthcare companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI), and Sarepta Therapeutics (SRPT). Veracyte received a reiterated Buy rating from William Blair and an upgrade to Buy from TipRanks – DeepSeek. Maravai Lifesciences Holdings maintained a Hold rating from Guggenheim and William Blair, while Sarepta Therapeutics received a Buy rating from Mizuho Securities.
Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives
Maravai LifeSciences Holdings (MRVI) reported a US$130.8 million trailing twelve-month loss for FY 2025, with revenue of US$185.7 million, sparking concerns about its path to profitability. The company's recent quarterly losses and a five-year pattern of widening losses challenge narratives of margin recovery, despite management's efforts to implement over US$50 million in annualized cost savings. While the stock trades at a P/S of 2.8x, lower than peers, and has a DCF fair value of US$7.10 against a current price of US$3.56, analysts remain divided on its future prospects given its unprofitability and slower revenue growth compared to the US market.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported its financial results for the fourth quarter and full year ended December 31, 2025, exceeding revenue expectations and returning to positive Adjusted EBITDA in Q4. The company announced quarterly revenue of $49.9 million and an annual revenue of $185.7 million, with a net loss of $(63.0) million and $(230.8) million respectively. Maravai also provided full-year 2026 guidance, projecting revenue between $200 million and $210 million and Adjusted EBITDA between $18 million and $20 million, driven by a focus on operational excellence and revenue growth.
Maravai LifeSciences (NASDAQ: MRVI) posts 2025 loss but targets 2026 EBITDA rebound
Maravai LifeSciences (NASDAQ: MRVI) reported a challenging 2025 with significant revenue decline and a net loss, primarily due to reduced demand for its CleanCap vaccine orders. Despite this, the company saw slightly positive Adjusted EBITDA in Q4 2025, driven by cost reductions. Looking ahead, Maravai projects a rebound in 2026, guiding for increased revenue and a return to positive Adjusted EBITDA, as it focuses on operational excellence and growth.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported its fourth quarter and full year 2025 financial results, exceeding revenue expectations and returning to positive Adjusted EBITDA in Q4. The company announced full year 2026 revenue guidance of $200 million to $210 million and Adjusted EBITDA guidance of $18 million to $20 million, driven by operational excellence and cost reduction efforts. Financial performance was impacted by a decrease in TriLink revenue due to a lack of high-volume CleanCap orders, while Cygnus revenue saw an increase.
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY)
This article summarizes recent analyst ratings for three healthcare companies. Stifel Nicolaus maintained a Buy rating for Thermo Fisher (TMO) with a $700 price target, while Bank of America Securities issued a Sell rating for Phibro Animal Health (PAHC) with a $32 price target. Noble Financial reiterated a Buy rating for Unicycive Therapeutics (UNCY) with a $60 price target, noting a significant potential upside.
Investor group (NASDAQ: MRVI) reports 7.23% Maravai LifeSciences stake
An investor group has filed an amended Schedule 13G/A, reporting a beneficial ownership of 10,486,451 Class A common shares, which represents 7.23% of Maravai LifeSciences Holdings, Inc. The group includes various entities like Hudson View Holdings LLC and JD Squared Holdings II LLC, along with individuals such as Stuart Feldman. The filing explicitly certifies that the shares were not acquired to change or influence the control of Maravai LifeSciences.
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY)
Analysts have provided new ratings for several healthcare companies. Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Thermo Fisher (TMO) with a $700.00 price target, suggesting a strong upside. Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Phibro Animal Health (PAHC), while Noble Financial's Robert LeBoyer reiterated a Buy rating on Unicycive Therapeutics (UNCY) with a significant price target of $60.00, implying a substantial upside.
Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking five-year losses to 90%
Maravai LifeSciences Holdings (NASDAQ:MRVI) has seen its stock price drop by 90% over the last five years, including an 11% decline this past week and 32% over the last twelve months. The company is not currently profitable, and its revenue has shrunk by 21% per year over the last five years. Despite the poor financial performance, there has been some significant insider buying in the last three months, which could be a positive sign.
MRVI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Maravai LifeSciences Holdings, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who purchased shares between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its revenue recognition, internal controls, and goodwill, leading to an overstatement of its financial prospects. Shareholders with losses during this period have until May 5, 2025, to seek appointment as lead plaintiff.
Maravai ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. The investigation follows a class action complaint filed after Maravai announced errors in revenue recognition, a material weakness in internal controls, and a potential non-cash impairment charge related to a past acquisition, causing a significant drop in share price. The law firm is encouraging affected investors to contact them for more information.
A US$75m Market Cap Boost Pleasing ToMaravai LifeSciences Holdings Insiders
Maravai LifeSciences Holdings (NASDAQ:MRVI) experienced a 16% stock increase last week, adding US$75m to its market capitalization, which was pleasing for insiders who bought shares over the past year. Insiders, notably CEO Bernd Brust, collectively purchased US$1.9m worth of shares, indicating a positive outlook although the company did not make a profit in the last year. Insider ownership stands at 2.5%, aligning management's interests with smaller shareholders.
MRVI INVESTOR ALERT: Kirby McInerney LLP Reminds Maravai Lifesciences Holdings, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
Kirby McInerney LLP is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI) that the lead plaintiff deadline for a federal securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai failed to disclose inadequate internal controls over revenue recognition and an overstatement of goodwill, leading to a significant stock price decline on February 25, 2025, after the company announced delays in its earnings release and annual report due to an identified error in revenue recognition and a potential non-cash impairment charge. Investors who purchased Maravai securities during the Class Period (August 7, 2024, through February 24, 2025) are encouraged to contact the law firm to discuss their rights.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRVI
Rosen Law Firm is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI) that the lead plaintiff deadline for a securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its financial reporting and goodwill. Investors who purchased Maravai securities between August 7, 2024, and February 24, 2025, are encouraged to secure counsel.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Maravai LifeSciences Holdings, Inc. (MRVI) Shareholders
Levi & Korsinsky has filed a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of shareholders who suffered losses due to alleged securities fraud between August 7, 2024, and February 24, 2025. The lawsuit claims that Maravai made false statements and concealed issues regarding its internal controls over financial reporting, leading to inaccurate revenue recognition and an overstatement of goodwill. Shareholders affected during this period are encouraged to seek information on potential recovery.
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) announced its third quarter 2025 financial results, reporting revenue of $41.6 million, a net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million. Despite a decline in Nucleic Acid Production revenue due to fewer high-volume CleanCap orders, the company projects full-year 2025 revenue of approximately $185.0 million and anticipates double-digit sequential revenue growth for TriLink in Q4 2025. The company leadership expressed confidence in their restructuring initiatives to deliver attractive financial results for the remainder of 2025 and 2026.
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
Maravai LifeSciences Holdings, Inc. announced its financial results for the third quarter and first nine months of 2025. The company reported a revenue of $41.6 million for Q3 2025, a 39.7% decrease year-over-year, and a net loss of $(45.1) million. The decrease was primarily attributed to a lack of high-volume CleanCap orders, though its Biologics Safety Testing segment saw a 7.2% revenue increase.
MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is continuing its investigation into Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. This follows a class action complaint alleging that Maravai made materially false or misleading statements and failed to disclose critical information regarding revenue recognition errors and internal control weaknesses. The investigation focuses on whether Maravai's board of directors breached their fiduciary duties, especially after the company postponed its 2024 earnings release and reported a material weakness in internal controls over revenue recognition, causing a significant stock drop.
MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders following a class action complaint filed on March 3, 2025. The investigation stems from Maravai postponing its fiscal 2024 earnings and delaying its 10-K filing due to an identified error in revenue recognition of approximately $3.9 million, a material weakness in internal controls, and a potential non-cash impairment charge related to an acquisition. This news caused Maravai's share price to drop 21.70% to $3.14 on February 25, 2025.
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. Investors who purchased MRVI securities between November 10, 2020, and May 10, 2022, have until October 24, 2023, to apply to be lead plaintiff. The lawsuit alleges that Maravai made false and misleading statements regarding its business, operations, and prospects, and failed to disclose that its COVID-19 revenue was unsustainable and would decline.
Levi & Korsinsky Notifies Shareholders of Maravai LifeSciences Holdings, Inc.(MRVI) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky has notified shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) about a class action lawsuit. This notice highlights an upcoming deadline for shareholders to potentially participate in the lawsuit. The specific details of the lawsuit and the deadline are not provided in this snippet.
Maravai LifeSciences Holdings, Inc. (MRVI) Faces Securities Class Action After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman
Hagens Berman has announced a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (MRVI) due to the company's delayed Q4 and FY 2024 earnings report and admission of improper revenue recognition. This revelation led to a significant 23% drop in Maravai's stock price. Investors who suffered losses are encouraged to contact Hagens Berman for more information on the lawsuit and their potential claims.
MRVI Stock Drop: What Investors Should Know
Maravai LifeSciences Holdings Inc. (MRVI) stock dropped significantly by -7.56% on March 19, 2025, amidst multiple class action lawsuits alleging securities fraud, false financial reporting, and inadequate internal controls. The company is facing scrutiny over overstated goodwill, inaccurate revenue recognition, and a Q4 adjusted loss of $0.06 per diluted share. Despite substantial liquidity and total assets, legal challenges and troubling financial signals are creating uncertainty and a cautious sentiment among investors, with one analyst advising a level-headed trading strategy over emotional reactions.
Maravai LifeSciences Holdings, Inc. Class Action: The Gross Law Firm Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVI
The Gross Law Firm is reminding investors of Maravai LifeSciences Holdings, Inc. (MRVI) about a pending class action lawsuit. Investors who purchased MRVI securities between November 10, 2022, and May 7, 2024, are encouraged to contact the firm to learn about their rights. The deadline to apply to be a lead plaintiff in the lawsuit is May 5, 2025.
Maravai LifeSciences Announces Organizational Restructuring and Cost Reduction Initiatives Aiming for $50 Million in Annual Savings | MRVI Stock News
Maravai LifeSciences announced an organizational restructuring and cost reduction initiatives targeting over $50 million in annual savings after reporting a 31.7% year-over-year revenue decline in Q2 2025. The company, which saw a 5% increase in its base business revenue, expects to achieve positive adjusted EBITDA and free cash flow by the second half of 2026. Leadership changes include Bernd Brust as CEO and Raj Asarpota as CFO, as Maravai aims to realign its cost structure and minimize operational disruption.
The Gross Law Firm Notifies Shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm has issued a notice to shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) regarding a class action lawsuit. The lawsuit alleges that Maravai LifeSciences Holdings, Inc. issued materially false and misleading statements concerning its revenue recognition and goodwill. Shareholders who purchased MRVI shares between August 7, 2024, and February 24, 2025, are encouraged to contact the firm by the May 5, 2025 deadline to potentially be appointed as lead plaintiff.
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRVI
This article from Rosen Law Firm encourages investors in Maravai Lifesciences Holdings, Inc. (MRVI) to secure legal counsel due to an approaching deadline in a securities class action lawsuit. Investors who purchased MRVI securities between May 6, 2021, and November 10, 2023, may be eligible to join the class action. The lawsuit alleges that Maravai made materially false and misleading statements regarding its business, operations, and prospects.
MARAVAI LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc. - MRVI
Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., has launched an investigation into Maravai LifeSciences Holdings, Inc. (NasdaqGS: MRVI). This investigation follows Maravai's disclosure of delayed annual report filing due to a revenue recognition error and potential impairment charge, which led to an ongoing securities class action lawsuit against the company and its executives. KSF is examining whether Maravai's officers and directors breached their fiduciary duties or violated laws, inviting long-term shareholders to contact them regarding their legal rights.
MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire,
Bragar Eagel & Squire, P.C. has launched an investigation into Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. This follows a class action complaint filed against Maravai for allegedly making false and misleading statements and failing to disclose material adverse facts regarding its financial reporting and revenue recognition. The investigation focuses on whether Maravai's board of directors breached their fiduciary duties after the company announced delays in its earnings release and identified errors in revenue recognition and potential goodwill impairment.
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. This investigation follows a class action complaint filed on March 3, 2025, which alleges that the company made false and misleading statements and failed to disclose material adverse facts, including issues with revenue recognition, internal controls, and overstated goodwill. The announcement comes after Maravai postponed its fiscal 2024 earnings release and delayed its annual report due to an identified error in revenue recognition and a material weakness in internal controls.
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Maravai LifeSciences reported its second quarter 2025 financial results, showing a 31.7% decrease in total revenue year-over-year, primarily due to lower CleanCap orders. The company announced a major organizational restructuring and cost reduction plan targeting over $50 million in annualized savings and appointed a new CEO and CFO to drive innovation and improve financial performance. Maravai expects a reduction in net loss, positive Adjusted EBITDA, and positive free cash flow by the second half of 2026, while withdrawing its full-year 2025 revenue guidance during its business review.
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported its second-quarter 2025 financial results, with revenue of $47.4 million, a net loss of $(69.8) million, and adjusted EBITDA of $(10.4) million. The company announced an organizational restructuring and cost reduction initiatives aimed at over $50 million in annualized savings, and it expects a net loss reduction, positive Adjusted EBITDA, and positive free cash flow by the second half of 2026. Maravai also appointed Bernd Brust as CEO and Raj Asarpota as CFO to drive innovation and performance.
Maravai Launches Major $50M Restructuring Plan as New CEO Takes Helm Amid Earnings Challenge
Maravai LifeSciences reported challenging Q2 2025 financial results with a significant revenue decline and a net loss, including a goodwill impairment. In response, new CEO Bernd Brust and CFO Raj Asarpota announced a major restructuring plan targeting over $50 million in annualized cost savings. The company has withdrawn its 2025 guidance and aims for net loss reduction, positive Adjusted EBITDA, and positive free cash flow by the second half of 2026.
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. on behalf of long-term stockholders. This follows a class action complaint filed against Maravai, citing alleged breaches of fiduciary duties and misleading statements regarding revenue recognition and internal controls. The investigation stemmed from Maravai's announcement of postponing its 2024 earnings release due to an error in revenue recognition and a material weakness in internal controls.
MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating
Bragar Eagel & Squire, P.C., a shareholder rights law firm, is investigating Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. This investigation follows a class action complaint filed due to alleged breaches of fiduciary duties concerning an error in revenue recognition and a potential non-cash impairment charge. The firm encourages affected investors to contact them for more information.
MRVI SEC Filings - Maravai Lifesciences Holdings, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Maravai Lifesciences Holdings (MRVI) SEC filings, including annual/quarterly reports and material event forms, for investors. It highlights recent filings such as a CFO appointment, insider stock awards for multiple directors, and the associated compensation details. The platform also offers AI-powered tools to summarize these regulatory disclosures.
Maravai ALERT: Bragar Eagel & Squire, P.C. is Investigating
Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. This investigation follows a class action complaint filed against Maravai due to identified errors in revenue recognition, a material weakness in internal controls, and a potential non-cash impairment charge related to goodwill. The company's stock price fell significantly after these issues were announced.
